Phase 2 Zika vaccine trial begins in US, Central and South America

(NIH/National Institute of Allergy and Infectious Diseases) Vaccinations have begun in a multi-site Phase 2/2b clinical trial testing an experimental DNA vaccine designed to protect against disease caused by Zika infection. The vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID)). NIAID is leading the trial, which aims to enroll healthy participants in areas of confirmed or potential active mosquito-transmitted Zika infection, including continental United States and Puerto Rico, Brazil, Peru, Costa Rica, Panama and Mexico.

https://www.eurekalert.org/pub_releases/2017-03/nioa-p2z033117.php

Source: EurekAlert! - Medicine and Health - March 31, 2017 Category: Global & Universal Source Type: news